Northwest Biotherapeutics Stock Draws Interest Concerning DCVax (NASDAQ:NWBO)

Northwest Biotherapeutics, Inc. (NASDAQ:NWBO)

As the Dow dropped below 16,000 while not disappointing at 15,976, let’s focus on Northwest Biotherapeutics stock symbol NWBO. The Company (www.nwbio.com) surged +24.13% Up 1.11 with 5.2 million shares in play Monday November 18, 2013. What’s the issue about Northwest Biotherapeutics on the stock market you ask? The answer is DCVax®.

DCVax®  is a specified immune therapies for solid tumor cancers. The global market for cancer therapies is expected to reach around 157.9 billion by 2013. DCVax® was previously  featured in news coverage on both Fox News and Fox Business News. Dr. Siegel stated that some patients with Glioblastoma multiforme in preliminary trials have witnessed their survival times more than double from what would be expected under the current standard of care. To find out more concerning DCVax®  visit (www.nwbio.com/product_candidates_platforms.php) via the web

****

Crown Equity Holdings Inc. (OTCMKTS:CRWE)   

Lets observe Crown Equity Holdings stock symbol CRWE. Crown Equity Holdings (http://crownequityholdings.com) provides a array networks of services such as website, HR, IR, advertisement and video streaming services such a CRWETube (http://crwetube.com/). Crown Equity Holdings has recently founded iB2B Global. iB2B Global is a global B2B trade online directory for wholesale and retailers. To view iB2B Global short form business plan visit (http://crownequityholdings.com/extras/iB2BGlobal_business_plan.pdf), via the internet. 

Some analyst expect that U.S., ecommerce should rake in around $262.3 billion in sales for 2013. What makes this a topic of interest is the growth projection expectation by 2017. iB2B Global expects to achieve $10 to $15 million in total EBITA by the end of their third year. Crown Equity Holdings has experienced +354.54% positive traction concerning Crown Equity Holdings 52 week low.  

Remember: Always do your homework and consult your own financial professional.

Read Full Disclaimer at http://crwewallstreet.com/disclaimer/